Bart Grelinger, MD
Neurology · Wichita, KSNPI 1730184433
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for neurology clinicians in KS, where the typical reported total is $830.
Across 29 payments — averaging $21.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$97
- AbbVie$77
- Novartis$56
- Globus Medical$55
- Biogen$46
- UCB, Inc.$45
- plus $250 from 12 others
Across 2 payments — averaging $4332.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$9K
What the payments were for
- Food & beverage$625100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 4 | $97 |
| AbbVie(2 entities) | 4 | $77 |
| Novartis | 3 | $56 |
| Globus Medical | 1 | $55 |
| Biogen | 2 | $46 |
| UCB, Inc. | 2 | $45 |
| Argenx US, Inc. | 1 | $34 |
| Medtronic | 2 | $28 |
| Johnson & Johnson | 1 | $22 |
| Bristol Myers Squibb | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Nevro Corp. | 1 | $20 |
| Genentech USA, Inc. | 1 | $20 |
| Banner Life Sciences, LLC | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Amgen | 1 | $18 |
| Siemens Medical Solutions USA, Inc. | 1 | $16 |
| GE HealthCare | 1 | $13 |
How this compares
$625 in reported general payments places this provider in the 45th percentile of 131 neurology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CopaxoneGlatiramer Acetate | 23 | $148,313 |
| TecfideraDimethyl Fumarate | 12 | $110,165 |
| RytaryCarbidopa/Levodopa | 51 | $43,459 |
| Dimethyl Fumarate | 58 | $23,866 |
| GlatopaGlatiramer Acetate | 13 | $23,650 |
| Emgality PenGalcanezumab-Gnlm | 31 | $22,699 |
| Aimovig AutoinjectorErenumab-Aooe | 30 | $22,274 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $18,580 |
| Nurtec OdtRimegepant Sulfate | 14 | $15,061 |
| BotoxOnabotulinumtoxina | 11 | $12,676 |
| Dalfampridine ErDalfampridine | 30 | $8,953 |
| EliquisApixaban | 12 | $7,015 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 336 | $7,008 |
| Lacosamide | 16 | $6,481 |
| Memantine Hcl ErMemantine Hcl | 77 | $6,385 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenTecfidera | $46 | $110,16512 claims |
| AbbVieBotox | $77 | $12,67611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 131 neurology providers in Kansas.
Other neurology in Wichita
- Mohammed HussainWichita$7K
- Pedro Vivar CruzWichita$5K
- Rajesh SadasivuniWichita$4K
- Ricky LeeWichita$1K
- Gautham ReddyWichita$1K
- Ivan OsorioKansas City$101.7M
- Jeffrey KaplanLenexa$1.9M
- Rajesh PahwaKansas City$889K
- Sheetal MalikTopeka$137K
- Richard DubinskyKansas City$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.